Abstract
Alpha-1-antitrypsin (AAT) deficiency is a debilitating disease characterized by progressive parenchymal lung loss. Deficiency of AAT results in a protease-antiprotease imbalance with unregulated activity of neutrophil elastase (NE). This imbalance results in accelerated parenchymal lung damage and a subsequent decrease in pulmonary function. Repletion of AAT enzyme with augmentation therapy using human pooled AAT is the current standard for the treatment for AAT deficiency. While therapy with pooled AAT is the cornerstone of treatment in patients with AAT deficiency, patients should also benefit from proven treatments for other obstructive lung diseases like chronic obstructive pulmonary disease (COPD). Interventions such as smoking cessation, inhaled medications, pulmonary rehabilitation, supplemental oxygen therapy, vaccinations, avoidance of environmental exposures, and prophylactic antibiotics should be viewed as essential therapies in the management of AAT deficiency.
Keywords: Alpha-1-antitrypsin, alpha-1-antitrypsin deficiency, alpha-1-antitrypsin deficiency treatment. augmentation therapy, smoking cessation, pulmonary rehabilitation.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Utilization of Proven Therapies for Chronic Obstructive Lung Disease (COPD) in Patients with Alpha-1 Antitrypsin Deficiency
Volume: 10 Issue: 5
Author(s): Amit Mahajan and D. Kyle Hogarth
Affiliation:
Keywords: Alpha-1-antitrypsin, alpha-1-antitrypsin deficiency, alpha-1-antitrypsin deficiency treatment. augmentation therapy, smoking cessation, pulmonary rehabilitation.
Abstract: Alpha-1-antitrypsin (AAT) deficiency is a debilitating disease characterized by progressive parenchymal lung loss. Deficiency of AAT results in a protease-antiprotease imbalance with unregulated activity of neutrophil elastase (NE). This imbalance results in accelerated parenchymal lung damage and a subsequent decrease in pulmonary function. Repletion of AAT enzyme with augmentation therapy using human pooled AAT is the current standard for the treatment for AAT deficiency. While therapy with pooled AAT is the cornerstone of treatment in patients with AAT deficiency, patients should also benefit from proven treatments for other obstructive lung diseases like chronic obstructive pulmonary disease (COPD). Interventions such as smoking cessation, inhaled medications, pulmonary rehabilitation, supplemental oxygen therapy, vaccinations, avoidance of environmental exposures, and prophylactic antibiotics should be viewed as essential therapies in the management of AAT deficiency.
Export Options
About this article
Cite this article as:
Mahajan Amit and Kyle Hogarth D., Utilization of Proven Therapies for Chronic Obstructive Lung Disease (COPD) in Patients with Alpha-1 Antitrypsin Deficiency, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (5) . https://dx.doi.org/10.2174/1871523011109050368
DOI https://dx.doi.org/10.2174/1871523011109050368 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Treatment of Pulmonary Edema by ENaC Activators/Stimulators
Current Molecular Pharmacology Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Vasopressin-Receptor Antagonists: A New Class of Agents for the Treatment of Hyponatremia
Endocrine, Metabolic & Immune Disorders - Drug Targets Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1
Current Drug Targets Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design The Effects of Antihypertensive Therapy on Haemostatic Parameters
Current Pharmaceutical Design Inodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology Erectile Dysfunction and Diabetes Mellitus: Mechanistic Considerations from Studies in Experimental Models
Current Diabetes Reviews Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry Emerging Anabolic Treatments in Osteoporosis
Current Drug Safety Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design Beta-Blockers and Nitrates: Pharmacotherapy and Indications
Cardiovascular & Hematological Agents in Medicinal Chemistry Systemic Sclerosis-Related Pulmonary Hypertension: Unique Characteristics and Future Treatment Targets
Current Pharmaceutical Design Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
Current Pharmaceutical Design Clinical Applications of Cardiac Multi-Slice Computed Tomography
Current Medical Imaging Bisphosphonate Anticancer Activity in Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry Hypoxia Responsive Drug Delivery Systems in Tumor Therapy
Current Pharmaceutical Design